Elmar Kraus
Stock Analyst at DZ Bank
(2.86)
# 1,489
Out of 5,182 analysts
12
Total ratings
80%
Success rate
25.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Elmar Kraus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Hold | $820 | $874.00 | -6.18% | 4 | Feb 21, 2024 | |
| GSK GSK plc | Downgrades: Hold | n/a | $54.47 | - | 1 | Feb 11, 2022 | |
| AZN AstraZeneca | Upgrades: Hold | n/a | $186.68 | - | 1 | Feb 11, 2022 | |
| PFE Pfizer | Upgrades: Buy | $41 | $26.48 | +54.83% | 2 | Feb 4, 2021 | |
| MDT Medtronic | Downgrades: Hold | $92 | $81.90 | +12.33% | 2 | May 14, 2020 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $129.26 | - | 2 | Mar 18, 2020 |
Eli Lilly and Company
Feb 21, 2024
Downgrades: Hold
Price Target: $820
Current: $874.00
Upside: -6.18%
GSK plc
Feb 11, 2022
Downgrades: Hold
Price Target: n/a
Current: $54.47
Upside: -
AstraZeneca
Feb 11, 2022
Upgrades: Hold
Price Target: n/a
Current: $186.68
Upside: -
Pfizer
Feb 4, 2021
Upgrades: Buy
Price Target: $41
Current: $26.48
Upside: +54.83%
Medtronic
May 14, 2020
Downgrades: Hold
Price Target: $92
Current: $81.90
Upside: +12.33%
Gilead Sciences
Mar 18, 2020
Upgrades: Buy
Price Target: n/a
Current: $129.26
Upside: -